Quality Congress Aims to Elevate Clinical Trial Quality

Steve Whittaker, Executive Director of the Avoca Quality Consortium™

Steve Whittaker, Executive Director of the Avoca Quality Consortium™

Steve Whittaker, Executive Director of the Avoca Quality Consortium™, is looking forward to the 2018 Quality Congress, developed by the Association of Clinical Research Professionals and The Avoca Group.

“This is a great venue for us to come together and determine how we work in harmony to improve clinical trials at all levels,” Whittaker says.

The Avoca Group, whose clients include top five pharmaceutical companies and global contract research organizations (CROs), is a driving force behind the continuous improvement of outsourced clinical research. In 2011, the Avoca Quality Consortium (AQC), a pre-competitive collaborative, was formed. Members include more than 80 pharma, biotech, and clinical service providers.

Among many sessions that will take place at the 2018 Quality Congress, Whittaker highlights Operationalizing Risk-Based Approaches in Light of ICH E6 (R2) and a Focus on Inspection Preparedness Across the Entire Clinical Trial Ecosystem (View Event Details).

The session focuses on “operationalizing a mixed-based approach to things in light of ICH E6 (R2), and to focus on inspection preparedness across the entire clinical trial ecosystem.” It’ll be an interactive session designed to review ongoing efforts to expand and enhance the content and robustness of the AQC Inspection Readiness and Preparedness Knowledge Center to include site-centric leading practices, tools and inspection site experiences.

Last year, ACRP and Avoca announced a new strategic partnership dedicated to driving quality, efficiency, and collaboration in clinical research. This year’s Quality Congress will be an industry first.

Author: Michael Causey